SCHEMBL15065749

SCHEMBL15065749

Cc1cnc(N)c(C(F)(F)F)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
GRM5 P41594 2/20 0.34
KDM5B Q9UGL1 1/20 0.34
IDO1 P14902 1/20 0.33
TLR7 Q9NYK1 1/20 0.32
MTOR P42345 2/20 0.32
MAPKAPK2 P49137 1/20 0.32
PIK3CD O00329 1/20 0.32
PIK3C2B O00750 1/20 0.32
PIK3R1 P27986 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
PIK3CG P48736 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26783154 0.85 HSP90AA1 (0.38) HSP90AA1HSP90AB1KDM4EHPGDHSD17B10
SCHEMBL15471371 0.83 NOS3 (0.35) KDM4ENOS3NOS1NOS2GRM5
SCHEMBL25164736 0.80 KDM5B (0.35) HSP90AA1HSP90AB1KDM4EHPGDHSD17B10
Ammonia Solution, Strong SCHEMBL28037154 0.78 KDM5B (0.34) HSP90AA1HSP90AB1KDM4EKDM5BCOMT
SCHEMBL25301572 0.77 KDM5B (0.33) HSP90AA1HSP90AB1KDM4EKDM5BCOMT
SCHEMBL670030 0.76 HTT (0.37) KDM4EGRM5
SCHEMBL30863409 0.76 HTT (0.37) KDM4EGRM5
SCHEMBL28270253 0.76 KDM5B (0.35) HSP90AA1HSP90AB1KDM4EHPGDHSD17B10
SCHEMBL17375392 0.74 CDK2 (0.37) KDM4EGRM5MAPKAPK2PIK3CD
SCHEMBL20839189 0.74 KDM4E (0.32) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023122093-A1 REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-06-29 WO disclosed
WO-2023122093-A1 REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-06-29 WO disclosed
EP-3684184-B1 HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2023-06-21 EP disclosed
US-20220144801-A1 HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2022-05-12 US disclosed
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
EP-2797592-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2019-08-28 EP disclosed
EP-2797592-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2019-08-28 EP disclosed
WO-2019057723-A1 HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2019-03-28 WO disclosed
US-20170320848-A1 COMPOUNDS FOR USE IN ANTHELMINTHIC TREATMENT BAYER ANIMAL HEALTH GMBH (DE) 2017-11-09 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
CN-104244944-A Compounds for treating spinal muscular atrophy PTC THERAPEUTICS INC 2014-12-24 CN disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320848-A1 COMPOUNDS FOR USE IN ANTHELMINTHIC TREATMENT ACHE, COX5B, TUBB6 HSP90AA1 699/4885HSP90AB1 789/4885KDM4E 2155/4885
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 HSP90AA1 1578/4885HSP90AB1 1485/4885KDM4E 829/4885
US-20220144801-A1 HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES DDT, HPD, PLPBP HSP90AA1 2335/4885HSP90AB1 1944/4885KDM4E 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.